The $1M monthly sales milestone is a positive signal for a micro-cap regenerative medicine company, but without prior-period comparisons or profitability data, the stock reaction may be muted. Monitor the next quarterly filing (10-Q) for sustained revenue growth and margin trends before adjusting positions.
Price Chart
Executive Summary
Zeo ScientifiX announced that for the first time in company history, its unaudited monthly sales surpassed $1 million in April 2026. This is a positive commercial milestone for a small regenerative medicine company, but the filing provides no comparative prior-period data, profitability metrics, or guidance, making the magnitude of the achievement difficult to assess.
Key Facts
- Unaudited monthly sales surpassed $1 million in April 2026, a first for the company.
- The company attributes growth to a newly implemented internal sales force and physician education masterclass programs.
- No prior-period monthly sales figures, profitability data, or forward guidance were provided in the filing.
- The company trades on the OTCQB exchange (ZEOX) and is classified as an emerging growth company.
Financial Impact
April 2026 unaudited monthly sales exceeded $1 million; no comparative prior-period data or profitability information provided.
Risk Factors
- No comparative prior-period data provided, making it impossible to assess the growth rate or trend.
- The company is an OTC-traded micro-cap with limited liquidity and higher volatility.
- Forward-looking statements about scaling the sales force and physician network are aspirational and not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-004982 |
| Document: zeoscientifix_ex99-1.htm | 0001829126-26-004982 |
| Document: 0001829126-26-004982-index-headers.html | 0001829126-26-004982 |
| Document: 0001829126-26-004982-index.html | 0001829126-26-004982 |
| Document: 0001829126-26-004982.txt | 0001829126-26-004982 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+20 | — | — |
Sep 15, 2026 5w ago | 8-K | $1.36 $1.15 | ▼ −15.44% | ▼ −18.42% | $1.59 (+16.91%) |
Sep 1, 2026 7w ago | 8-K | $1.20 $1.39 | ▲ +15.83% | ▲ +14.65% | $1.59 (+32.50%) |
Aug 4, 2026 11w ago | 8-K | $1.40 $1.20 | ▼ −14.16% | ▼ −12.93% | $1.59 (+13.73%) |
Jul 21, 2026 13w ago | 8-K | $1.69 $1.55 | ▼ −8.28% | ▼ −10.85% | $1.59 (−5.92%) |
Jul 8, 2026 15w ago | 8-K | $1.80 $1.40 | ▼ −22.33% | ▼ −25.61% | $1.59 (−11.67%) |
Jul 1, 2026 16w ago | 8-K | $1.77 $1.65 | ▼ −6.78% | ▼ −4.59% | $1.59 (−10.17%) |
Jun 16, 2026 18w ago | 8-K | $1.72 $1.94 | ▲ +12.79% | ▲ +11.93% | $1.59 (−7.56%) |
Jun 9, 2026 19w ago | 8-K | $1.67 $1.80 | ▲ +7.78% | ▲ +6.39% | $1.59 (−4.79%) |
May 27, 2026 21w ago | 8-K | $1.85 $1.70 | ▼ −8.11% | ▼ −6.21% | $1.59 (−14.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers